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Serial Angioscopic Assessment of Coronary
Stent Lining with Antiplatelet or Anticoagulant
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The most effective pharmacologic regimen to inhibit subacute coronary stent
thrombosis has yet to be defined with certainty. To assess the effects of
different antithrombotic therapies on thrombus deposition and early tissue
reaction in stented coronary arteries we performed serial angioscopy in 20
consecutive pts who received Palmaz-Schatz coronary stent. Pts were ran-
domized in a 3: 1 ratio to receive either ticlopidine (250 mg b.i.d.1 and aspirin
(325 mg day) (Group 1, 15 pts) or continuous Lv. heparin (titrated to APTI
of 60-100 seconds) combined with aspirin (325 mg day) and dipyridamole
175 mg t.i.d.1 (Group 2, 5 ptsl. until the day 7th. Long term treatment was
only with ticlopidine and aspirin. Coronary angioscopy was performed pre
stenting, immediately post implant (Imml. on day 7th (Wk) and 2 months
later (Mth). All indications for stenting were included; 7 pts (35%) had mul-
tiple stents placed. High pressure low compliant balloons were chosen for
complete stent expansion. Angioscopic images were categorised unaware
of therapeutic treatment.
No pts suffered subacute stent thrombosis. Conclusions: The angioscopic
features of covering reactions in stented coronary arteries are time depen-
dent and not completely similar in the two tested antithrombotic regimens.
1) Coverage was absent or very thin and focally distributed on day 7th. 2)
Completion of the neointimallining was obtained in 2 months in the majority
of patients. 31 Early intense patchy red reaction was only seen in the an-
tiplatelet treated group. 4) Thrombus deposition was rare, without evidence
of occlusive thrombus. Ticlopidine + aspirin may promote an early angio-
scopic tissue reaction similar but not equal to that induced by standard anti-
coagulation.
~ ns). Clinical endpoints at 6 months follow-up (N = 84) were: death (S: 0,
A: 01. myocardial infarction (S: 0, A: 01, stroke (S: 0, A: 01. elective CABG (S:
2, A: 1). re-PTCA (S :5, A: 7). At follow-up, a clinical endpoint was reached
by 24% of patients in the S (10/42) versus 29% (12/42) in the A-group (P =
ns). Angiographic endpoints were: early closure (S: 1, A: 3) and restenosis
(2:50% reduction of the reference diameter at repeat angiography) (S: 19/40,
(48%) and A: 14/40, (35%1. P = ns). The minimal luminal diameter increased
from 0.97 ± 0.27 mm (S) versus 1.08 ± 0.38 mm (A) (baseline, P ~ nsl to
2.81 ± 0.48 mm (S) versus 2.42 ± 0.59 mm (A) (post procedure, P = 0.0021
and to 1.80 ± 0.99 mm (S) versus 1.73 ± 0,79 mm (A) (follow-up, P = ns),
In conclusion, both Wiktor S and A are safe and immediately effective
therapeutic options in symptomatic patients with obstructive right coronary
artery disease. Despite a larger postprocedural MLD with S, no difference in
angiographic result is observed at 6 months, As a consequence, the clinical
outcome is comparable at 6 months follow-up.
The association between Apolipoprotein E (apo E) alleles (,2, ,3 and ,4),
dyslipidemias, and coronary heart disease (CHD) prevalence was studied in
a community-based sample of middle-aged men (n = 1034) and women (n
= 916) aged 40-77 years, participating in a long term study of cardiovascu-
lar disease. Compared with the 83 allele, the ,4 allele was associated with
elevated LDL-C (2:4,14 mmollL [160 mg!dL]) in women, the £2 and 84 alle-
les were associated with moderately elevated triglycerides (2:2.82 mmol!L
[250 mg!dL]) in men, and the ,2 allele was associated with severely elevated
triglycerides (>5.64 mmollL [500 mg/dL]) in men. The apo E alleles were not
associated with hypertension, obesity, smoking, or diabetes, but the ,4 al-
lele frequency was reduced in women after age 60 years. The age-adjusted
prevalence of CHD was associated with the ,4 allele in men (relative odds
= 1.53, P = 0.037) and women (relative odds = 1.99, P = 0.0491. In anal-
yses for women and for both sexes combined this relation persisted after
adjustment by hypertension, smoking, obesity, diabetes, HDL-C, and LDL-
C. Conclusion: Apo E alleles are important genetic markers for dyslipidemia
and CHD. The estimated CHD odds associated with the ,4 allele appears to
be greater than that for any other known genetic lipid abnormality, and the
,4 allele association with CHD remains significant in women and both sexes
combined after adjustment by traditional coronary risk factors and lipids.
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The REgression GRowth Evaluation Statin Study (REGRESS) is a two year
double blinded placebo controlled prospective atherosclerosis regression
study, primarily investigating pravastatin treatment by means of quantitative
coronary analysis in a 885 male population with coronary disease.
In the REGRESS ultrasound substudy, 255 patients received five B-mode
scans, which were used to do intima-media thickness (IMTI measurements
of three carotid and two femoral arterial wall segments. One of the aims was
to detect a difference in the change of the combined far walllMT's between
the pravastatin and the placebo group (respective baseline values: age 56.8
(8.1) and 55,2 (7,7); LDL-chol. 4.36 (0.80) and 4.33 (0.79) mmol/l; mean far
wall IMT 0.88 (0.34) and 0.91 (0.33)mm, p ~ 0.41). Pravastatin treatment
caused a stable decrease in LDL-chol. of 1.4(0.8) mmol~ (p < 0.001) after
two months, Multivariate repeated measurements variance analysis showed
a statistically significant effect of pravastatin (p < 0.0011 on the mean com-
bined far walilMT. The largest effect was observed in the common femoral
artery: 0.09 mm. (SEO,05) decrease in the pravastatin, and 0 13 mm (SE 0.05)
increase in IMT in the placebo group.
Conclusion: Pravastatin induced a decrease in far walilMT.
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Between July 1992 and March 1994,84 patients, with documented ischemia
related to new onset right coronary artery stenoses, were randomly assigned
to either endoluminal stenting (S) (42 S) with the Wiktor device or conven-
tional balloon angioplasty (A) (42 A). Both groups were comparable for base-
line clinical, angiographical and procedural variables. Clinical endpoints at
hospital discharge (N = 84) were: death (S: 0, A: 0), myocardial infarction (S:
0, A: 01. stroke (S: 1, A: 01. emergency CABG (S: 1, A: 0), cross-over or failure
of either treatment (S: 1, A: 3), composite endpoint (S: 3 (7%1. A: 3 (7%), P
Francisco Fernandez-Aviles, Joaquin Alonso, Juan M. Duran, Federico Gimeno,
Juan C. Munoz, Luis Fuente, Alberto San Roman, Enrique Guillem. Hospital
Universitario, Valladolid, Spain
Subacute thrombotic occlusion and bleeding complications related to an-
tithrombotic therapy are the major limitations of elective coronary stenting.
The effectiveness of a new antithrombotic regimen without full early antico-
agulation to prevent these complications has been evaluated in 52 consec-
utive pts (62 ± 11 years, 82% male) who underwent elective Palmaz-Schatz
stenting in 58 lesions. Four lesions were restenotic and 3 lesions were lo-
cated in venous graft. The mean reference diameter was 3.3 ± 0.6 mm, with
a mean diameter stenosis of 71 ± 9%.
Intravenous heparin was given only during the procedure. After stenting,
the pts were treated with aspirin, dipyridamole, dextran, warfarin and sub-
cutaneous low molecular weight heparin ILMWH) [enoxaparine, 40 mg/day].
LMWH was started 6 h after stenting and stopped when an INR of 2-3 was
achieved, The aPTI and the INR were determined daily before discharge. In
